Theralase Technologies Inc. (CVE:TLT - Get Free Report) was down 10.6% during trading on Wednesday . The company traded as low as C$0.21 and last traded at C$0.21. Approximately 122,607 shares traded hands during trading, an increase of 2% from the average daily volume of 119,964 shares. The stock had previously closed at C$0.24.
Theralase Technologies Stock Performance
The stock has a market capitalization of C$49.92 million, a PE ratio of -10.92 and a beta of 1.36. The business's fifty day moving average is C$0.27 and its two-hundred day moving average is C$0.25. The company has a quick ratio of 3.40, a current ratio of 1.91 and a debt-to-equity ratio of 14.85.
Theralase Technologies Company Profile
(
Get Free Report)
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Recommended Stories
Before you consider Theralase Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theralase Technologies wasn't on the list.
While Theralase Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
